Lenz & Staehelin advised private equity healthcare specialist Archimed on its acquisition of a majority stake in family-owned ExcellGene and sister company Magellan Biologics & Consulting, both active in the biologic therapeutics sector. The deal
Search Results for: Lenz & Staehelin
Lenz & Staehelin advised Prof. Dr. Martin Janssen in connection with the sale of Ecofin Investment Consulting – a company founded by Janssen himslef – to the Vaudoise Group. The company Headquartered in Zurich, Ecofin Investment Consulting
Hello everyone, welcome to our weekly newsletter, SSW. Let’s go through the news highlights of this week now coming to an end. Advestra advised SGS in connection with the issuance of EUR 1 billion bonds.
Lenz & Staehelin has successfully defended Swiss telecom provider Swisscom, in a competition law investigation. The context The investigation pivoted around the case by which Swisscom had charged too high prices in various tenders for
Lenz & Staehelin advised BNP Paribas on the Swiss merger filing concerning BNP Paribas Cardif’s acquisition of AXA Investment Managers (AXA IM). BNP Paribas Cardif is the insurance subsidiary of BNP Paribas. The transaction,
Welcome back to Signed, Sealed, Weekend, we’re on with our first newsletter episode after the summer break. Let’s dive right-into what happened this past week all across the Swiss legal market. Starting from
Lenz & Staehelin advised the shareholders of Fire System, a Swiss fire safety solutions specialist, on their strategic partnership with Trajan Capital, a French private equity firm specialised in supporting entrepreneurs and mid-sized companies. The
Winterthur-based Rieter – a globally active supplier of systems for manufacturing yarn – has closed a CHF 750 million syndicated financing. The syndicate behind the operation included UBS Switzerland and Zürcher Kantonalbank, as well as a group
Lenz & Staehelin advised software and cloud solutions provider SoftwareOne throughout closing of a CHF 1.26 billion syndicated financing, with Niederer Kraft Frey representing the lenders. The syndicate arranging the operation included BNP Paribas, UBS Switzerland,
Lenz & Staehelin represented Samsung Bioepis – part of the Samsung Bioepis group, the developer of the biosimilar Pyzchiva – in a patent nullity proceedings before the Swiss Federal Patent Court. On 12 August 2025, the Court upheld a
